A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

Phase 1 Completed 24 enrolled Hanmi Pharmaceutical Company Limited

NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects

Timeline

Start: 2022-08-02
Primary completion: 2022-10-25
Completion: 2022-10-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RLD2202	Unknown	—	—
Subject	RLD2203	Unknown	—	—

Indications

No indication recorded.